| Drug General Information |
| Drug ID |
D03BHZ
|
| Former ID |
DIB007007
|
| Drug Name |
AZD8186
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 1 |
[1],
[2]
|
|---|
| Company |
Astrazeneca
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C24H25F2N3O4
|
| InChI |
InChI=1S/C24H25F2N3O4/c1-14(27-18-11-16(25)10-17(26)12-18)19-8-15(24(31)28(2)3)9-20-21(30)13-22(33-23(19)20)29-4-6-32-7-5-29/h8-14,27H,4-7H2,1-3H3/t14-/m1/s1
|
| InChIKey |
LMJFJIDLEAWOQJ-CQSZACIVSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
PI3K beta |
Target Info |
Inhibitor |
[3]
|
|---|
|
BioCyc Pathway
|
Superpathway of inositol phosphate compounds
|
|
3-phosphoinositide biosynthesis
|
|
KEGG Pathway
|
Inositol phosphate metabolism
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Phosphatidylinositol signaling system
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
Jak-STAT signaling pathway
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Regulation of actin cytoskeleton
|
|
Insulin signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Aldosterone-regulated sodium reabsorption
|
|
Carbohydrate digestion and absorption
|
|
Bacterial invasion of epithelial cells
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Measles
|
|
Influenza A
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Proteoglycans in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Apoptosis signaling pathway
|
|
Axon guidance mediated by netrin
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Hypoxia response via HIF activation
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
Integrin signalling pathway
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
T cell activation
|
|
VEGF signaling pathway
|
|
p53 pathway
|
|
Ras Pathway
|
|
p53 pathway feedback loops 2
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
ErbB4 signaling events
|
|
LPA receptor mediated events
|
|
TRAIL signaling pathway
|
|
Signaling events mediated by TCPTP
|
|
FAS (CD95) signaling pathway
|
|
CXCR4-mediated signaling events
|
|
EGF receptor (ErbB1) signaling pathway
|
|
Class I PI3K signaling events
|
|
ErbB1 downstream signaling
|
|
ErbB2/ErbB3 signaling events
|
|
PDGFR-beta signaling pathway
|
|
Nephrin/Neph1 signaling in the kidney podocyte
|
|
Internalization of ErbB1
|
|
CXCR3-mediated signaling events
|
|
Reactome
|
PI3K Cascade
|
|
GPVI-mediated activation cascade
|
|
PIP3 activates AKT signaling
|
|
PI3K/AKT activation
|
|
Role of phospholipids in phagocytosis
|
|
Tie2 Signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
DAP12 signaling
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
Nephrin interactions
|
|
G beta:gamma signalling through PI3Kgamma
|
|
VEGFA-VEGFR2 Pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Interleukin receptor SHC signaling
|
|
Regulation of signaling by CBL
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
DNA Damage Response (only ATM dependent)
|
|
G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
Insulin Signaling
|
|
Fc epsilon receptor (FCERI) signaling
|
|
PI Metabolism
|
|
Interleukin-2 signaling
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
DAP12 interactions
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
PIP3 activates AKT signaling
|
|
Signaling Pathways in Glioblastoma
|
|
TCR signaling
|
|
Signaling by PDGF
|
|
Signaling by Insulin receptor
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Nephrin interactions
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
GPVI-mediated activation cascade
|
|
Cell surface interactions at the vascular wall
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Regulation of toll-like receptor signaling pathway
|
|
AMPK Signaling
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01884285) AZD8186 First Time In Patient Ascending Dose Study. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8527). |
|---|
| REF 3 | National Cancer Institute Drug Dictionary (drug id 751594). |
|---|
